Loading
companiesCompany
Chugai Pharmaceutical
Chugai is a Tokyo pharmaceutical company majority-owned by Roche that discovered alectinib for ALK-positive lung cancer and sells Roche's cancer medicines in Japan.
Also called: Chugai中外製薬
Overview
Chugai Pharmaceutical, listed in Tokyo and majority-owned by Roche since 2002 while remaining a separately listed company, is one of Japan's largest drug makers and its most important source of cancer medicines. It discovered the ALK inhibitor alectinib (Alecensa), developed worldwide with Roche, and markets Roche's oncology portfolio in Japan, including atezolizumab, trastuzumab, bevacizumab and polatuzumab vedotin, alongside its own antibody engineering platforms. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.
Headquarters
Tokyo, JP
Scorecard
All companies#48of 1244 companies, score 73
- approved products +18
- targets +8
- modalities +8
- regions +7
- 24-month regulatory events +2
- registry trials +30
3 approved, 0 in phase 3, 0 earlier, 4 targets, 2,032 registry studies. Formula on the scorecards page.
Type
Stage
Public
ApprovedSmall-molecule kinase inhibitor (ALK)
Alectinib · Alecensa
Alectinib is a well-tolerated ALK pill, standard first line for years and, since 2024, the first targeted therapy given after surgery for ALK-positive lung cancer.
ApprovedMonoclonal antibody (anti-PD-L1)
Atezolizumab · Tecentriq / Tecentriq Hybreza (SC)
A PD-L1 blocker used in lung, liver, and bladder cancer. In 2026 it became the first drug approved based on a blood test showing leftover cancer after bladder surgery.
ApprovedADC
Polatuzumab vedotin · Polivy
Polatuzumab vedotin is an ADC against CD79b that, swapped into the classic R-CHOP regimen, became the first improvement on frontline lymphoma therapy in twenty years.
EstablishedRecombinant glycosylated G-CSF, injection
Lenograstim · Granocyte
Lenograstim is Europe's and Japan's glycosylated form of G-CSF, given after chemotherapy to shorten the period of dangerously low neutrophils and to mobilise stem cells for transplant; it does the same job as filgrastim.
Similar pages
- TrialA Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Shares Alectinib, Atezolizumab, Roche / Genentech, Non-small-cell lung cancer.
- TrialA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
Shares Alectinib, Atezolizumab, Roche / Genentech, Non-small-cell lung cancer.
- TrialA Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small C
Shares Alectinib, Roche / Genentech, Non-small-cell lung cancer.
- TrialA Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
Shares Atezolizumab, Roche / Genentech, Non-small-cell lung cancer.
- TrialALESIA
Shares J-ALEX, Alectinib, Roche / Genentech.
- TrialPharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms
Shares Alectinib, Non-small-cell lung cancer.
- TrialA Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
Shares Polatuzumab vedotin, Roche / Genentech.
- TrialSX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
Shares Atezolizumab, Non-small-cell lung cancer.
cancers
fronts
drugs
ApprovedSmall-molecule kinase inhibitor (ALK)
Alectinib · Alecensa
ApprovedMonoclonal antibody (anti-PD-L1)
Atezolizumab · Tecentriq / Tecentriq Hybreza (SC)
EstablishedRecombinant glycosylated G-CSF, injection
Lenograstim · Granocyte
ApprovedADC
Polatuzumab vedotin · Polivy